Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 23;10(7):763.
doi: 10.3390/antibiotics10070763.

Use of Ceftaroline in Hospitalized Patients with and without COVID-19: A Descriptive Cross-Sectional Study

Daniele Roberto Giacobbe  1   2 , Chiara Russo  1   2 , Veronica Martini  3 , Silvia Dettori  1   2 , Federica Briano  1   2 , Michele Mirabella  2 , Federica Portunato  2 , Chiara Dentone  2 , Sara Mora  4 , Mauro Giacomini  4 , Marco Berruti  1   2 , Matteo Bassetti  1   2
Affiliations

Use of Ceftaroline in Hospitalized Patients with and without COVID-19: A Descriptive Cross-Sectional Study

Daniele Roberto Giacobbe et al. Antibiotics (Basel). .

Abstract

A single-center cross-sectional study was conducted to describe the use of ceftaroline in a large teaching hospital in Northern Italy, during a period also including the first months of the coronavirus disease 2019 (COVID-19) pandemic. The primary objective was to describe the use of ceftaroline in terms of indications and characteristics of patients. A secondary objective was to describe the rate of favorable clinical response in patients with bloodstream infections (BSI) due to methicillin-resistant Staphylococcus aureus (MRSA-BSI) receiving ceftaroline. Overall, 200 patients were included in the study. Most of them had COVID-19 (83%, 165/200) and were hospitalized in medical wards (78%, 155/200). Included patients with COVID-19 pneumonia were given empirical ceftaroline in the suspicion of bacterial co-infection or superinfection. Among patients with MRSA-BSI, ceftaroline was used as a first-line therapy and salvage therapy in 25% (3/12) and 75% (9/12) of cases, respectively, and as a monotherapy or in combination with daptomycin in 58% (7/12) and 42% (5/12) of patients, respectively. A favorable response was registered in 67% (8/12) of patients. Improving etiological diagnosis of bacterial infections is essential to optimize the use of ceftaroline in COVID-19 patients. The use of ceftaroline for MRSA-BSI, either as a monotherapy or in combination with other anti-MRSA agents, showed promising rates of favorable response.

Keywords: COVID-19; MRSA; Staphylococcus aureus; ceftaroline.

PubMed Disclaimer

Conflict of interest statement

Outside the submitted work, D.R.G. reports honoraria from Stepstone Pharma GmbH and unconditional grants from MSD Italia and Correvio Italia. Outside the submitted work, M.B. (Matteo Bassetti) has received funding for scientific advisory boards, travel and speaker honoraria from Angelini, Astellas, AstraZeneca, Basilea, Bayer, BioMérieux, Cidara, Correvio, Cubist, Menarini, Molteni, MSD, Nabriva, Paratek, Pfizer, Roche, Shionogi, Tetraphase, Thermo Fisher, and The Medicine Company. All the other authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Distribution of MRSA and MSSA as etiological agents in patients without coronavirus disease 2019 (COVID-19) treated with ceftaroline. The figure includes etiological agents isolated both before and after initiation of ceftaroline therapy (i.e., isolates both from patients receiving targeted therapy and from patients receiving empirical ceftaroline with subsequent isolation of the causative agent). Indications are not mutually exclusive. BSI, bloodstream infection; CAP, community-acquired pneumonia; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; SSTI, skin and soft tissue infection.
See this image and copyright information in PMC

References

    1. European Medicines Agency Zinforo 600 mg Powder for Concentrate for Solution for Infusion: Summary of Product Characteristics. [(accessed on 1 May 2021)]; Available online: https://www.ema.europa.eu/en/documents/product-information/zinforo-epar-....
    1. Bassetti M., Russo A., Cilloniz C., Giacobbe D.R., Vena A., Amaro R., Graziano E., Soriano A., Torres A. Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain. Int. J. Antimicrob. Agents. 2020;55:105921. doi: 10.1016/j.ijantimicag.2020.105921. - DOI - PubMed
    1. Burnett Y.J., Echevarria K., Traugott K.A. Ceftaroline as Salvage Monotherapy for Persistent MRSA Bacteremia. Ann. Pharmacother. 2016;50:1051–1059. doi: 10.1177/1060028016664361. - DOI - PubMed
    1. Cortes-Penfield N., Oliver N.T., Hunter A., Rodriguez-Barradas M. Daptomycin and combination daptomycin-ceftaroline as salvage therapy for persistent methicillin-resistant Staphylococcus aureus bacteremia. Infect. Dis. 2018;50:643–647. doi: 10.1080/23744235.2018.1448110. - DOI - PMC - PubMed
    1. Gritsenko D., Fedorenko M., Ruhe J.J., Altshuler J. Combination Therapy With Vancomycin and Ceftaroline for Refractory Methicillin-resistant Staphylococcus aureus Bacteremia: A Case Series. Clin. Ther. 2017;39:212–218. doi: 10.1016/j.clinthera.2016.12.005. - DOI - PubMed

Grants and funding

LinkOut - more resources